Clinical Trial Update: Phase II Study of TAS-106 to Treat Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase II study of TAS-106 for head and neck cancer was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• TAS-106

Snippet

Sponsor: Taiho Pharmaceutical Co., Ltd. | Conditions: Head and Neck Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-09-05